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several hurdles remain between laboratory 
practice and successful clinical translation. 
One approach—termed personalized anti-
tumor immune-therapy—involves the for-
mulation of patient’s own tumor-derived 
components into an anticancer vaccine.[6,7]
Personalized immune-therapy imple-
menting patient’s own tumor tissue of the 
patient, collected from a biopsy or from 
surgery, might hold promise to raise the 
potency and tumor-specific immunity of 
cancer vaccines. The design of patient-
derived cancer cell vaccines can involve 
three different methods, i.e., identifica-
tion of neo-antigens, preparation of tumor 
cell lysate or the use of intact cancer cells. 
The first approach requires analysis of the 
genome of patient-derived cells to identify 
proteins that are absent from the normal 
human genome and exclusively rise from 
tumor-specific mutations.[8,9] This method 
however is complex, labor intensive, and 
costly. In contrast to this first approach, 
preparation of cancer cell lysate from the 
cancer tissue of the patient is less complex 
and includes neo-antigens as well as nonmutated tumor antigens, 
preferentially leading to a broader immune response.[7,10] Third, 
incorporation of intact tumor cells can be an interesting approach 
as in this case all cell components such as cell membrane proteins 
are also involved and when translated to whole tumor tissue, also 
offer the possibility to coencapsulate stromal proteins. Vaccines 
Targeting the immune system with a personalized vaccine containing cues 
derived from the patient’s malignancy might be a promising approach in the 
fight against cancer. It includes neo-antigens as well as nonmutated tumor 
antigens, preferentially leading to an immune response that is directed to a 
broader range of epitopes compared to strategies involving a single antigen. 
Here, this paper reports on an elegant method to encapsulate whole cancer 
cells into polyelectrolyte particles. Porous and nonaggregated microparticles 
containing dead cancer cells are obtained by admixing mannitol and live 
cancer cells with oppositely charged polyelectrolytes, dextran sulfate (anionic 
polysaccharide), and poly-l-arginine (cationic polypeptide) prior to atomiza-
tion into a hot air stream. It shows that the polyelectrolyte-enrobed cancer 
cells, upon redispersion in phosphate buffered saline buffer, are stable and 
do not release cell proteins in the supernatant. In vitro experiments reveal 
that the particles are nontoxic and strongly increase uptake of cell lysate by 
dendritic cells. In vitro assessment of antigen presentation by dendritic cells 
reveal the potential of the polyelectrolyte-enrobed cancer cells as promotors 
of antigen cross-presentation. Finally, it is demonstrated that the immuno-
genicity can be enhanced by surface adsorption of a polymer-substituted 
TLR7-agonist.
Immunotherapy
1. Introduction
Antitumor therapy that involves dendritic cells (DCs) to evoke 
a tumor-specific immune response is an attractive alternative 
to classic chemo- and irradiation therapy as it avoids the side-
effects associated to the latter therapies.[1–5] Unfortunately, 
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comprising autologous cell material can be an alternative for exis-
iting vaccines based on allogenic tumor cell lines involving GVAX, 
a granulocyte-macrophage colony-stimulating factor(GM-CSF) 
gene-transfected tumor cell vaccine, encountering human leuco-
cyte antigen (HLA) mismatch resulting in an anti-HLA reponse 
rather than a tumor antigen-directed reponse.[11]
In this paper, we describe a simple, yet efficient, strategy 
to formulate whole cancer cell lysate into microparticles and 
demonstrate that this process enhances antigen cross-presenta-
tion by DCs. By admixing live cells in aqueous medium with 
oppositely charged polypeptides and polysaccharides followed 
by atomization into a hot air stream, a complex coacervate is 
formed surrounding the cells through spray drying. Evapora-
tion of the water phase during the atomization process yields 
a dry powder composed of polyelectrolyte-enrobed cancer cells. 
This approach is schematically illustrated in Figure 1. Our 
method generates a whole cell-based lysate within a single 
polyelectrolyte complex coacervate microparticle, and ensures—
owing to the atomization/drying step—all cells to be dead in 
the final formulation. The latter avoids, upon administration, 
regrowth of new tumors due to residual living cells, as often the 
case with whole cell based lysates. In addition, our spray drying 
approach yields a dry particle formulation which can easily be 
stored over prolonged times and is highly attractive if one envi-
sions multiple administrations over longer periods of time.[12–14]
2. Results and Discussion
As a model cancer cell line we used the murine Lewis lung car-
cinoma cell line (LLC.OVA) that is stably transfected with a non-
secreted, truncated form of ovalbumin (tOVA). The latter will act 
as tumor-associated model antigen and allows a straightforward 
read-out of the immunological response by OVA-based assays.
2.1. Preparation of Polyelectrolyte-Enrobed Cancer Cells
In a first series of experiments we examined whether spray 
drying of living cancer cells was feasible applying similar 
conditions as previously determined in our laboratories for 
spray-drying of soluble proteins and polymers.[15–18] An LLC.
OVA cell suspension, at a density of 60 × 106 cells per 10 mL 
deionized water, was stirred on ice to minimize cell lysis and 
aggregation. Subsequently, mannitol, dextran sulfate (DEXS), 
and poly-l-arginine (PLARG) were added a 40:4:5 (w/w) ratio. 
The role of mannitol is to enhance the microparticle recovery 
yield after the atomization step, to reduce protein denaturation 
and to generate porosity in the polyelectrolyte coacervate matrix 
which enhances protease influx and degradation of the matrix 
upon uptake by dendritic cells as shown in our earlier work.[16] 
As control, microparticles were prepared without cells. Both 
formulations comprised a dry powder with an average recovery 
yield (calculated from the initial solid mixture amount) 
of ≈50%. Scanning electron microscopy (SEM) imaging 
(Figure 2 – panel 1) revealed that the cell-containing particles 
exhibited a slightly more irregularly shape compared to the 
empty control particles. Redispersion of the microparticles in 
phosphate buffered saline (PBS; pH 7.4, 150 × 10−3 m NaCl) 
results both in case of cell-containing microparticles and the 
empty control microparticles in the formation of a nonag-
gregated suspension, as confirmed by optical microscopy 
(Figure 2 – panel 2). This implies that the presence of cell 
material does not drastically change the spray drying process 
and stable cell-containing microparticles can be obtained. It 
should be noted that the obtained microparticles are polydis-
perse which is related to the spray drying process and cannot 
be avoided. Transmission electron microscopy (TEM) imaging 
(Figure 2 – panel 3) revealed that the control particles had a 
relatively homogenous porous interior. By contrast, micropar-
ticles produced from LLC.OVA cells exhibit a more complex 
internal structure, which can likely be attributed to the pres-
ence of cellular components that yield high contrast on TEM, 
such as lipid-rich domains, ER, and the nuclear envelope.
To assess whether each component in the formulation is 
required to obtain a stable microparticle suspension in PBS, 
we prepared control samples containing only cells, cells mixed 
with mannitol but no polyelectrolytes, and cells mixed with 
mannitol and only DEXS or PLARG. As illustrated in Figure S1 
(Supporting Information), none of these conditions were suc-
cessful. Spray drying of cells only resulted in an extremely low 
yield, similar to what we previously observed for spray drying of 
proteins and polymers in absence of mannitol.[16] Moreover, the 
recovered amount of material could not properly be redispersed 
again in PBS. Samples containing mannitol but no polyelectro-
lytes and samples containing mannitol and either one of both 
polyelectrolytes had decent yield (i.e., ≈50%), but only resulted 
in microparticles upon redispersion in PBS in case of cells/
mannitol/PLARG. However, the latter was highly aggregated, 
which we attribute to ionic gelation of the PLARG by the divalent 
phosphate anions in PBS. When redispersion was performed 
in deionized water, again no microparticles were found. These 
findings clearly demonstrate the need for mannitol, DEXS and 
PLARG to prepare microparticles at a sufficient recovery yield 
and with the ability to be properly redispersed in PBS.
Next, sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) was used to analyze, whether upon 
redispersion in PBS, protein release from the microparticles 
occurred and thus to assess the encapsulation efficiency. We 
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Figure 1. Schematic illustration of the production of polyelectrolyte-
enrobed whole cell microparticles. Live cells are mixed in aqueous 
solution with dextran sulfate (negatively charged polysaccharide) and 
poly-l-arginine (positively charged polypeptide). Atomization of this sus-
pension in a heated air flow produces dry microparticles composed of 
single dead cells enrobed with a polyelectrolyte matrix.
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monitored the particle suspension itself and the supernatant 
comparing the cell-containing microspheres with a lyophilized 
cell suspension obtained from the same amount of cells as 
used for the preparation of the cell-containing microparticles. 
As shown in Figure 3A (left panel – supernatant), relative to 
the lyophilized cell control sample (lane 3), no protein release 
was detected in the supernatant of the centrifuged micropar-
ticle suspension (lane 2). This clearly shows the strength of the 
formed polyelectrolyte matrix surrounding the cells as no cell 
proteins are released from the particles upon redispersion. In 
addition, we also visualized the microparticle suspension itself 
(Figure 3A: right panel – suspension) to rule out the possi-
bility of the released proteins to be aggregated or precipitated. 
This revealed very little protein was present when the micro-
particle suspension itself was loaded onto the SDS-PAGE gel 
(lane 2) compared to the lyophilized control sample (lane 3) and 
confirms the efficient encapsulation of the cell proteins. As a 
control, empty microparticles were also included (i.e., without 
cells) to exclude interference of the microparticle components. 
As shown in lane 1 of Figure 3A, the empty microparticles 
indeed could not be detected on the SDS-PAGE gel. Additional 
UV–vis measurements were conducted to quantify the amount 
of released proteins in the supernatant upon redispersion of 
the cell-containing microparticles. However, no proteins could 
be dectected in the supernatant confirming our previous find-
ings obtained via SDS-PAGE.
Further visual proof of successful encapsulation of cel-
lular proteins into polyelectrolyte coacervate microparticles 
was gained by using the fluorescent eGFP expressing cell line 
CT5.3, a murine colon tumor-derived cell line. A microparticle 
Adv. Sci. 2017, 4, 1700050
Figure 2. Scanning electron (1), optical (2), and (3) transmission electron microscopy images of A) empty microparticles and B) LLC.OVA containing 
microparticles. Scale bar is 20 µm in (1) and (2) and 2 µm in (3).
Figure 3. A) Assessment of the encapsulation efficiency upon redispersion in PBS via SDS-PAGE recorded from the supernatant and suspension of 
(1) empty microparticles, (2) LLC.OVA containing microparticles, and (3) lyophilized LLC.OVA cells. B) Fluorescence microscopy image of a micropar-
ticle produced from the eGFP expressing CT5.3 cells.
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suspension prepared from this cell line exhibited a homoge-
neous green fluorescence throughout the microparticle volume 
(Figure 3B), without the presence of fluorescence in the sur-
rounding medium. This was confirmed by fluorimetry and 
indicated an encapsulation efficiency of nearly 100%.
2.2. In Vitro Evaluation of Polyelectrolyte-Enrobed Cancer Cells
First, cytotoxicity of the microparticles was evaluated by MTT 
assay. This revealed the particles to be nontoxic up to a concentra-
tion of 0.5 mg mL−1 as depicted in Figure 4A. Next, we assessed 
the in vitro uptake of the microparticles by the murine dendritic 
cell line DC2.4. For this purpose, microparticles produced from 
eGFP-positive CT5.3 cells were used to allow for straightforward 
detection by fluorescence-based methods. Flow cytometry was 
used to compare microparticle formulated cells with lyophilized 
cells. Note that both samples contained the same concentration 
of cell-based material. From these data (Figure 4B) it was clear 
that formulated microparticles resulted in a more efficient cel-
lular association of cell lysate in a dose-dependent manner. Sub-
sequently, confocal microscopy (Figure 4C) on similarly treated 
DC2.4 cells verified that the microparticles were indeed internal-
ized by the DCs and were not merely bound to the cell membrane.
Whereas soluble antigens are predominantly presented via 
MHC-II peptide complexes by DCs to CD4+ T-cells, formulation 
of soluble antigens into microparticles is known to enhance 
cross-presentation via MHC-I by DCs. The latter is essential for 
the priming of cytotoxic CD8+ T-cells that hold the capacity to 
recognize tumor cells and eliminate these via secretion of per-
forin and granzymes.[17–19] Here we investigated whether encap-
sulation of cell lysate into polyelectrolyte microparticles also 
promoted antigen presentation via MHC-I. In this experiment, 
microparticles containing LLC.OVA cells were used. Successful 
processing and MHC-I presentation of the ovalbumin, as model 
tumor-associated antigen, in the cell lysate would enable a flow 
cytometric detection of the SIINFEKL OVA-CD8+ epitope pre-
sented by MHC class I H-2Kb molecules via antibody staining. 
After 48 h of incubation with different particle concentrations, 
DC2.4 cells were stained and analyzed by flow cytometry. 
Figure 5 clearly shows a dose-dependent increase of the cross-
presentation efficiency when LLC.OVA cells were encapsulated 
in microparticles, whereas control experiments with lyophilized 
LLC.OVA cells did not show any significant cross-presentation. 
Neither was this the case for empty microparticles.
2.3. Coformulation of Polyelectrolyte-Enrobed Cancer Cells with 
Immune-Stimulating Cues
After formulation of tumor antigens into particles to augment 
cross-presentation, a potent cancer vaccine additionally requires 
Adv. Sci. 2017, 4, 1700050
Figure 4. In vitro evaluation of spray dried cell-derived polyelectrolyte microspheres on DC2.4 cells: A) MTT assay (n-6). B) Flow cytometry analysis of 
uptake efficiency (n-3). C) Confocal microscopy imaging of the interaction of the cell-containing microspheres compared to lyophilized cells with DCs. 
The cell membrane is stained with AF555-labeled cholera toxin B (CTB-AF555) and the cell nuclei are stained with Hoechst. Scale bar represents 15 µm.
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coformulation of particulate antigens with immune-stimulating 
cues to enhance the immunogenicity of the vaccine formula-
tion.[20–24] This is necessary because particle-based formulation 
alone is insufficient for potent cytotoxic T-cell (CTL)-induction 
as this process requires three signals: [1] interaction between 
the T-cell receptor and the MHC-I presented antigen on the DC 
surface; [2] interaction between the CD28 T-cell receptor and 
CD80 or CD86 on the DC surface; and [3] cytokine stimula-
tion of T-cells by DCs. The latter two signals can be mounted 
by triggering pathogen recognition receptors (PRRs) present at 
different location in DC, including cell surface and endosomal 
membranes and the cytoplasm. Amongst the multiple PRRs, 
Toll-like receptors (TLRs) have been widely explored as target 
for molecular adjuvants to skew TH1-driven immune responses 
and augment their amplitude and persistency. TLR7/8-trig-
gering is in particular attractive in the context of tumor vac-
cination as these receptors are present on the cell endosomal 
membrane in a wide range of both human and murine DC sub-
sets. Triggering leads to elevated levels of type I IFN and IL-12, 
which are key cytokines to promote TH1- and CTL-responses 
required for potent antitumor immune responses.[25–27] Inter-
estingly, small molecule agonists of TLR7/8 based on guano-
sine analogues and imidazoquinolines have been identified 
and polymer-conjugation of these molecules has recently been 
shown by us and others[28–30] as an ideal strategy to reduce their 
systemic dissemination, thereby greatly enhancing their toxicity 
profile, and to enhance their adjuvanticity toward coadminis-
tered antigens.
Here we used a polymer backbone composed of 
N-(hydroxypropyl) methacrylamide (HPMA) and N-(3-ami-
nopropyl) methacrylamide (APMA). Poly(HPMA-APMA)) 
containing 80 HPMA and 20 APMA repeating units was syn-
thesized via reversible addition-fragmentation chain transfer 
(RAFT) polymerization as earlier reported.[31] The primary 
amine moieties of this polymer were substituted with the 
TLR7/8-agonist 2-(4-((6-amino-2-(butylamino)-8-hydroxy-
9H_purin_9-yl)methyl)benzamido)acetic acid yielding TLR7-
poly(HPMA-APMA) (Figure 6).
The ability to coformulate this polymer with cell lysate into 
microparticles was tested using CT5.3-eGFP cells and rhoda-
mine labeled polymers that were synthesized by converting a 
small fraction of the poly(HPMA-APMA) amino groups with 
rhodamine-isothiocyanate. Confocal microscopy of the redis-
persed microparticles in PBS (Figure 7A) clearly demonstrated 
the presence of the polymer, predominantly in a dotted pattern, 
likely due to complexation with the polyelectrolytes, whereas 
the eGFP signal was clearly visible throughout the whole 
microparticle volume. Subsequently, microparticles were pro-
duced containing TLR-poly(HPMA-APMA). A TLR-reporter cell 
assay (i.e., RAW Blue) was performed to determine whether 
upon formulation into microparticles TLR-triggering is still 
possible. Note that RAW Blue cells are engineered RAW 264.7 
macrophages that express a broad range of PRRs and upon 
Adv. Sci. 2017, 4, 1700050
Figure 5. In vitro assessment of the MHC-I cross-presentation efficiency 
by DC2.4 cells.
Figure 6. Synthesis of poly(HPMA-APMA) and conjugation of the small molecule TLR7/8-agonist CL264.
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stimulation of these receptors produce secreted embryonic alka-
line phosphatase, which can easily be detected by UV–vis spec-
trophotometry. As shown in Figure 7B, LLC.OVA containing 
particles as well as poly(HPMA-APMA) did not evoke any acti-
vation evidenced by the lack of increase in absorbance relative 
to the negative PBS control. This suggested that the micropar-
ticles and the polymer on their own are poorly immunogenic.
Interestingly, the microparticles containing TLR-poly(HPMA-
APMA) strongly promoted TLR-activation almost equally effi-
ciently as the soluble TLR7/8-agonist opposed to the TLR-con-
taining polymer itself. This clearly shows the beneficial effect of 
particulate formulation of antigens together with TLR-agonists 
as attractive vaccine carriers. The increase in potency can be 
attributed to more efficient uptake of the particulate vaccine for-
mulation opposed to soluble vaccine which enables enhanced 
interaction of the TLR-ligand with its receptor upon cell uptake. 
As the TLR-poly(HPMA-APMA) did not seem to induce any 
maturation up to a TLR7-concentration of 0.44 × 10−6 m, higher 
concentrations were also tested in order to more clearly show the 
striking difference in activity of the TLR7-ligand when formu-
lated in particles or not. Indeed, the polymer alone only induces 
maturation starting from a TLR7-concentration of 0.56 × 10−6 m 
whereas the TLR7-containing particles already evoke activation 
at significantly lower concentrations. This decrease in efficiency 
of the polymer-linked TLR7/8-agonist can be attributed to steric 
hindrance of the polymer upon binding with the TLR-receptor 
and/or partial shielding of the active site of the TLR7/8-agonist. 
However, the latter is unlikely as both CL264 as well as other 
imidazoquinoline analogues have been conjugated at a similar 
position without fully abrogating their potency.[28,29,32]
3. Conclusion
In this paper we have reported on the formulation of whole 
cancer cells into solid polyelectrolyte-based coacervate micro-
particles formed by the oppositely charged biologically inspired 
polyelectrolytes. Relative to cell lysate produced by lyophiliza-
tion, microparticle-formulated cells were internalized by DCs 
to a much larger extent. Using a cancer cell line that stably 
expresses OVA as model tumor-associated antigen, we found 
that the antigen cross-presentation efficiency by DCs was sig-
nificantly enhanced in case of microencapsulated cells. We 
further demonstrated the ability to coencapsulate TLR7-ago-
nist-ligated polymers into the microparticles and verified that 
TLR-triggering can still occur. These findings pave the road for 
the development of whole cell based cancer vaccines that avoid 
the issue of tumor regrowth observed when using conditioned 
cancer cells and are more potent than soluble cell lysate based 
vaccines. In addition, since dry polyelectrolyte-enrobed cancer 
cells were obtained via spray drying, this formulation is highly 
stable and does not require cold chain preservation prior to 
administration into the patient unlike current liquid vaccine 
formulations. Further experiments will involve in vivo assess-
ment of the potency of the vaccine particles in triggering a 
robust antitumor immune response.
4. Experimental Section
Materials: Mannitol, dextran sulfate (10 kDa), poly-l-arginine 
hydrochloride (Mw > 70 kDa), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reagent, SDS, ethanol, dimethyl 
Adv. Sci. 2017, 4, 1700050
Figure 7. A) Confocal microscopy images of spray dried microspheres containing CT5.3-eGFP cell material and rhodamine-labeled poly(HPMA-APMA). 
Scale bar represents 10 µm. B) RAW blue assay comparison of the soluble TLR7-agonist, the polymer-ligated TLR7-agonist and the polyelectrolyte 
microspheres whether or not co-formulated with TLR7-poly(HPMA-APMA).
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sulfoxide (DMSO), NaHCO3, and paraformaldehyde were obtained from 
Sigma-Aldrich. Hydrochloric acid (HCl) 37% v/v and rhodamine-NHS 
were purchased from Fischer Scientific. Dulbecco’s modified 
Eagle medium (DMEM), RPMI 1640 medium, fetal bovine serum 
(EU qualified), penicillin/streptomycin (5000 U mL−1), sodium pyruvate 
(100 × 10−3 m), l-glutamine (200 × 10−3 m), cell dissociation buffer (PBS 
based), PBS buffer (pH 7.2), Hoechst, cholera toxine B conjugates to 
AlexaFluor555 (CTB-AF555), and Zeocin were obtained from Invitrogen. 
Laemli buffer (4x), 2-Mercaptoethanol, Coomassie blue stain (G-250), 
and 4–90 20% mini-protean TGX gels were purchased from Bio-rad 
whereas the pretreated Spectra/Por 7 dialysis membrane were 
purchased from Spectrumlabs. Quanti blue stain was obtained from 
Invivogen and antimouse OVA257-264 (SIINFEKL) peptide bound to 
H-2Kb PE antibody was purchased from eBioscience.
Cell Lines: LLC: OVA Cell Line: The LLC.OVA cell line was a kind gift 
from Prof. Karim Vermaelen (University of Ghent, Belgium). The cells 
were cultured in RPMI medium supplemented with 10% fetal bovine 
serum, 1% penicillin/streptomycin, 2 × 10−3 m l-glutamine, and 1 × 10−3 m 
sodium pyruvate and incubated at 37 °C with 5% CO2 saturation.
CT5.3-eGFP Cell Line: The CT5.3-eGFP cell line[33] was cultured 
in DMEM medium supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin, 2 × 10−3 m l-glutamine, and 1 × 10−3 m sodium 
pyruvate and incubated at 37 °C with 5% CO2 saturation.
DC2.4 Cell Line: The DC2.4 cell line was a kind gift from Dr. Kenneth Rock 
(University of Massachusetts, Boston, USA). The cells were cultured 
in RPMI medium supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin, 2 × 10−3 m l-glutamine, and 1 × 10−3 m sodium 
pyruvate and incubated at 37 °C with 5% CO2 saturation.
RAW Blue Cell Line: The RAW Blue cell line was purchased from 
Invivogen. The cells were cultured in DMEM medium supplemented with 
10% heat-inactivated fetal bovine serum, 1% penicillin/streptomycin, 
2 × 10−3 m l-glutamine, 1 × 10−3 m sodium pyruvate and 0.01% Zeocin 
and incubated at 37 °C with 5% CO2 saturation.
Synthesis of Cancer Cell Polyelectrolyte Microspheres: Prior to cell count, 
mannitol and DEXS were dissolved in 10 mL of lipopolysaccharide (LPS) 
free water to a concentration of 20 or 2 mg mL−1, respectively, and a 
5 mg mL−1 solution of PLARG was prepared in LPS free water. Next 60 × 106 
LLC.OVA cells were suspended in 15 mL of LPS free water and added 
to the mannitol–DEXS solution under stirring on ice. All handlings 
were performed in sterile conditions in a biohood to avoid endotoxin 
contamination. Subsequently, 5 mL of the poly-l-arginine solution was 
added dropwise under stirring to the cell suspension on ice prior to 
spray drying. Spray drying of the mixtures was performed on a lab-scale 
Buchi B2902 spray-dryer under sterile conditions. The latter involved 
presterilization of the spray dryer with ethanol and LPS free water 
prior to spray drying of the test samples. The spray-dryer operated in 
cocurrent air flow at drying air temperature of 130 °C. After spray drying 
the yield was determined and the obtained powder was stored at −20 °C. 
The samples were visualized on a Leica DM2500P microscope equipped 
with a 40× (NA 0.75) objective, DIC filter, and a DFC360FX camera after 
reconstitution in water. The initial weight of the LLC.OVA cell suspension 
was determined after lyophilization to calculate the yield after spray 
drying and of the amount of lyophilized cells needed as control.
Electron Microscopy: Scanning Electron Microscopy: SEM was 
performed on a Quanta 200 FEG FEI instrument. Samples were 
deposited onto a silicon wafer and dried under a gentle nitrogen stream 
at ambient temperature. Prior to imaging, the samples were sputtered 
with a palladium/gold coating.
Transmission Electron Microscopy: TEM was performed on a JEOL 1010 
instrument. Prior to imaging, samples were subjected to series of fixation 
(0.1 m Na cacodylate buffer (pH 7.2) containing 4% paraformaldehyde 
and 2.5% glutaraldehyde) and dehydration steps, embedded in epoxy 
resin and cut into ultrathin section using an ultramicrotome.
Gel Electrophoresis (SDS-PAGE): To analyze cell lysate encapsulation 
efficiency upon reconstitution of the particles after spray drying in 
LPS free water, gel electrophoresis was performed. The samples were 
diluted with a 1:9 2-mercaptoethanol:Laemli sample buffer solution (4x), 
incubated for 5 min at 95 °C and loaded on 4%–20% precast gels. After 
the run (150 kV), visualization of the protein bands was achieved by 
incubation of the gels into Coomassie blue stain.
MTT Assay: Cell viability was assessed by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. DC2.4 cells were 
seeded in 96-well plates at a density of 5 × 104 cells mL−1 (total volume 
100 µL) in sixfold. Subsequently, the cells were incubated with different 
concentrations of microspheres and lyophilized LLC.OVA cells and 
cultured for 24 h followed by addition of 40 µL of the MTT reagent 
(1 mg mL−1). After an incubation period of 2–3 h the formed formazan 
crystals were dissolved in 100 µL of a 10% m/v SDS/0.01 m HCl solution 
overnight protected from light. The absorbance was measured by a 
microplate reader at 570 nm. As a negative and positive control PBS 
buffer and DMSO, respectively, were added to the wells.
In Vitro Cell Uptake Assay: DC2.4 cells were seeded in a 24-well 
plate at a density of 0.15 × 106 cells mL−1 one day before the cells were 
pulsed with fluorescent particles at different concentrations. After 24 h 
of incubation, the cells were dissociated using cell dissociation buffer 
followed by centrifugation for 5 min at 200 G at 0 °C. After resuspension, 
the samples were stored on ice and measured on a BD Accuri C6 flow 
cytometer. The data were analyzed using FlowJo.
Confocal Microscopy: DC2.4 cells were seeded at a density of 
0.4 × 106 cells mL−1 in a glass bottom Will-co dish and incubated 
overnight. Next, the fluorescent particles were added, incubated for 24 h, 
and fixated in a 2% paraformaldehyde solution for 10–15 min. The cells 
were subsequently washed and simultaneously stained by CTB-AF555 and 
Hoechst for 1 h at room temperature. Finally, the samples were washed 
with PBS and imaging on a confocal microscope (Leica DMI6000 B 
inverted 241 microscope) equipped with an oil immersion objective (Zeiss, 
63×, 242 NA 1.40) and attached to an Andor DSD2 confocal scanner.
In Vitro MHC-I Presentation Assay: DC2.4 cells were seeded at a 
density of 0.2 × 106 cells mL−1 in a 24-well culture plate and incubated 
overnight followed by incubation with different concentrations of the 
samples. After 48 h at 37 °C the positive control (SIINFEKL) was added 
in triplicate in a concentration of 1 µg mL−1, 1 h prior to staining with 
SIINFEKL-MHC-I PE-labeled antibody for 30 min on ice protected from 
light. Subsequently, the samples were centrifuged for 5 min at 200 G at 
4 °C, resuspended in PBS and analyzed with flow cytometry.
Fluorescent Labeling of Poly(HPMA-APMA): Poly(HPMA-APMA) 
was incubated with an equimolar amount of rhodamine-NHS in 0.1 m 
NaHCO3 buffer overnight under continuous stirring. Subsequently, the 
obtained mixture was dialyzed against deionized water for 3 d (MWCO 
3.5 kDa) and lyophilized.
Polymer Synthesis and Conjugation of CL264: Poly(HPMA-APMA), 
dissolved in LPS free water, was incubated with an equimolar amount of 
TLR7-ligand CL264 to APMA units overnight under continuous stirring 
at room temperature in the presence of 1.5 m excess of DMTMM. After 
24 h incubation the reaction mixture was dialyzed against LPS free water 
(MWCO 3.5 kDa) for 1 d and lyophilized.
In Vitro RAW Blue Assay: RAW Blue macrophages were seeded 
in a 96 well round bottom plate at a density of 0.5 × 106 cells mL−1 
and immediately pulsed with the desired concentrations of the test 
compounds in sixfold. As a negative control PBS was added. After 24 h 
incubation, 50 µL of the supernatant was transferred into a 96 well flat 
bottom plate and incubated with 150 µL of Quanti blue solution. After 
3 to 6 h incubation at 37 °C the color change absorbance was measured 
with a plate reader at 620–655 nm.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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